Loading
PDBj
メニューPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

5TZL

Structure of transthyretin in complex with the kinetic stabilizer 201

5TZL の概要
エントリーDOI10.2210/pdb5tzl/pdb
分子名称Transthyretin, 4-(7-chloro-1,3-benzoxazol-2-yl)-2,6-diiodophenol (3 entities in total)
機能のキーワードtransthyretin, kinetic stabilizer, transport protein
由来する生物種Homo sapiens (Human)
タンパク質・核酸の鎖数2
化学式量合計28645.63
構造登録者
Connelly, S.,Mortenson, D.E.,Choi, S.,Wilson, I.A.,Powers, E.T.,Kelly, J.W.,Johnson, S.M. (登録日: 2016-11-21, 公開日: 2017-06-28, 最終更新日: 2023-11-15)
主引用文献Connelly, S.,Mortenson, D.E.,Choi, S.,Wilson, I.A.,Powers, E.T.,Kelly, J.W.,Johnson, S.M.
Semi-quantitative models for identifying potent and selective transthyretin amyloidogenesis inhibitors.
Bioorg. Med. Chem. Lett., 27:3441-3449, 2017
Cited by
PubMed Abstract: Rate-limiting dissociation of the tetrameric protein transthyretin (TTR), followed by monomer misfolding and misassembly, appears to cause degenerative diseases in humans known as the transthyretin amyloidoses, based on human genetic, biochemical and pharmacologic evidence. Small molecules that bind to the generally unoccupied thyroxine binding pockets in the native TTR tetramer kinetically stabilize the tetramer, slowing subunit dissociation proportional to the extent that the molecules stabilize the native state over the dissociative transition state-thereby inhibiting amyloidogenesis. Herein, we use previously reported structure-activity relationship data to develop two semi-quantitative algorithms for identifying the structures of potent and selective transthyretin kinetic stabilizers/amyloidogenesis inhibitors. The viability of these prediction algorithms, in particular the more robust in silico docking model, is perhaps best validated by the clinical success of tafamidis, the first-in-class drug approved in Europe, Japan, South America, and elsewhere for treating transthyretin aggregation-associated familial amyloid polyneuropathy. Tafamidis is also being evaluated in a fully-enrolled placebo-controlled clinical trial for its efficacy against TTR cardiomyopathy. These prediction algorithms will be useful for identifying second generation TTR kinetic stabilizers, should these be needed to ameliorate the central nervous system or ophthalmologic pathology caused by TTR aggregation in organs not accessed by oral tafamidis administration.
PubMed: 28625364
DOI: 10.1016/j.bmcl.2017.05.080
主引用文献が同じPDBエントリー
実験手法
X-RAY DIFFRACTION (1.4 Å)
構造検証レポート
Validation report summary of 5tzl
検証レポート(詳細版)ダウンロードをダウンロード

246905

件を2025-12-31に公開中

PDB statisticsPDBj update infoContact PDBjnumon